Cellect Biotechnology Stock Price, News & Analysis (NASDAQ:APOP)

$8.04 0.08 (1.01 %)
(As of 11/18/2017 11:16 AM ET)
Previous Close$8.04
Today's Range$7.82 - $8.13
52-Week Range$2.30 - $13.50
Volume13,528 shs
Average Volume113,042 shs
Market Capitalization$43.41 million
P/E RatioN/A
Dividend YieldN/A
Beta7.34

About Cellect Biotechnology (NASDAQ:APOP)

Cellect Biotechnology logoCellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:APOP
  • CUSIP: N/A
  • Web: cellectbio.com
Debt:
  • Current Ratio: 8.23%
  • Quick Ratio: 8.23%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.38 per share
  • Price / Book: 5.83
Profitability:
  • Trailing EPS: ($0.58)
  • Net Income: ($3,980,000.00)
  • Return on Equity: -102.64%
  • Return on Assets: -74.35%
Misc:
  • Employees: 18
  • Outstanding Shares: 5,440,000
 

Frequently Asked Questions for Cellect Biotechnology (NASDAQ:APOP)

What is Cellect Biotechnology's stock symbol?

Cellect Biotechnology trades on the NASDAQ under the ticker symbol "APOP."

When will Cellect Biotechnology make its next earnings announcement?

Cellect Biotechnology is scheduled to release their next quarterly earnings announcement on Monday, November, 27th 2017. View Earnings Estimates for Cellect Biotechnology.

Where is Cellect Biotechnology's stock going? Where will Cellect Biotechnology's stock price be in 2017?

2 analysts have issued 12-month target prices for Cellect Biotechnology's stock. Their predictions range from $1.00 to $14.00. On average, they anticipate Cellect Biotechnology's share price to reach $7.50 in the next twelve months. View Analyst Ratings for Cellect Biotechnology.

Who are some of Cellect Biotechnology's key competitors?

How do I buy Cellect Biotechnology stock?

Shares of Cellect Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellect Biotechnology's stock price today?

One share of Cellect Biotechnology stock can currently be purchased for approximately $8.04.

How big of a company is Cellect Biotechnology?

Cellect Biotechnology has a market capitalization of $43.41 million. The company earns ($3,980,000.00) in net income (profit) each year or ($0.58) on an earnings per share basis. Cellect Biotechnology employs 18 workers across the globe.

How can I contact Cellect Biotechnology?

Cellect Biotechnology's mailing address is 23 Hata'as Street, Kfar Saba L3, 44425. The company can be reached via phone at 972-9974-1444 or via email at [email protected]


MarketBeat Community Rating for Cellect Biotechnology (NASDAQ APOP)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about Cellect Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Cellect Biotechnology (NASDAQ:APOP)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.50 (6.72% downside)

Consensus Price Target History for Cellect Biotechnology (NASDAQ:APOP)

Price Target History for Cellect Biotechnology (NASDAQ:APOP)

Analysts' Ratings History for Cellect Biotechnology (NASDAQ:APOP)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017HC WainwrightReiterated RatingBuy -> Buy$12.00 -> $14.00MediumView Rating Details
4/4/2017Rodman & RenshawReiterated RatingBuy$10.00 -> $1.00HighView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History for Cellect Biotechnology (NASDAQ:APOP)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Cellect Biotechnology (NASDAQ:APOP)
Current Year EPS Consensus Estimate: $-1.56 EPS
Next Year EPS Consensus Estimate: $-1.35 EPS

Dividends

Dividend History for Cellect Biotechnology (NASDAQ:APOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cellect Biotechnology (NASDAQ APOP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Cellect Biotechnology (NASDAQ APOP)

Source:
DateHeadline
Solid Quant Score Make Cellect Biotechnology (APOP) a BuySolid Quant Score Make Cellect Biotechnology (APOP) a Buy
investorplace.com - November 13 at 4:24 PM
Cellect CEO, Dr. Shai Yarkoni Selected as Keynote Speaker at the 11th World Congress of Regenerative Medicine & Stem Cell in SingaporeCellect CEO, Dr. Shai Yarkoni Selected as Keynote Speaker at the 11th World Congress of Regenerative Medicine & Stem Cell in Singapore
finance.yahoo.com - November 10 at 2:02 PM
Cellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading CompaniesCellect Chosen Among Selected Global Leaders Presenting at Bio-Europe 2017 Conference Addressing over 3,800 Industry Specialists from Over 2,000 World Leading Companies
finance.yahoo.com - October 31 at 5:12 PM
Cellect Biotechnology’s (APOP) Solid Quant Score Keeps it a BuyCellect Biotechnology’s (APOP) Solid Quant Score Keeps it a Buy
investorplace.com - October 30 at 9:54 PM
Cellect Biotechnology’s (APOP) Solid Quant Score Keeps it a BuyCellect Biotechnology’s (APOP) Solid Quant Score Keeps it a Buy
investorplace.com - October 30 at 3:44 PM
Cellect Breakthrough Drives Stock Price UpwardCellect Breakthrough Drives Stock Price Upward
www.baystreet.ca - October 25 at 5:04 PM
Cellect Biotechnology (APOP) Reports Positive Results from 20 Patients Trial with Tel-Aviv Ichilov Medical CenterCellect Biotechnology (APOP) Reports Positive Results from 20 Patients Trial with Tel-Aviv Ichilov Medical Center
www.streetinsider.com - October 25 at 5:04 PM
Cellect Announces a Major Breakthrough of its ApoGraft™ Technology: Reporting Today Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical CenterCellect Announces a Major Breakthrough of its ApoGraft™ Technology: Reporting Today Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical Center
finance.yahoo.com - October 25 at 5:04 PM
Cellect Biotechnology Ltd. (APOP) Celebrates Major MilestoneCellect Biotechnology Ltd. (APOP) Celebrates Major Milestone
finance.yahoo.com - October 25 at 5:04 PM
Cellect Biotechnology’s (APOP) Strong Quant Score Makes it a BuyCellect Biotechnology’s (APOP) Strong Quant Score Makes it a Buy
investorplace.com - October 23 at 4:04 PM
Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development OfficerCellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer
finance.yahoo.com - October 19 at 4:32 PM
Cellect Biotechnology (APOP) a Buy on Robust Quant ScoreCellect Biotechnology (APOP) a Buy on Robust Quant Score
investorplace.com - October 16 at 5:17 PM
Cellect Biotechnology (APOP) Stock Rated a BuyCellect Biotechnology (APOP) Stock Rated a Buy
investorplace.com - October 9 at 3:38 PM
Cellect Biotechnology Ltd. (APOP) PT Raised to $14.00Cellect Biotechnology Ltd. (APOP) PT Raised to $14.00
www.americanbankingnews.com - September 25 at 7:56 AM
Corporate News Blog - Amicus Therapeutics Reports Phase-3 Results for Sd-101 in Epidermolysis Bullosa did not Meet Primary EndpointsCorporate News Blog - Amicus Therapeutics Reports Phase-3 Results for Sd-101 in Epidermolysis Bullosa did not Meet Primary Endpoints
finance.yahoo.com - September 15 at 4:19 PM
Cellect Biotechnology (APOP) Announces $4.3M Registered Direct Offering of ADSsCellect Biotechnology (APOP) Announces $4.3M Registered Direct Offering of ADSs
www.streetinsider.com - September 8 at 4:20 PM
Mid-Afternoon Market Update: NCI Building Drops On Downbeat Results; GoPro Shares Spike HigherMid-Afternoon Market Update: NCI Building Drops On Downbeat Results; GoPro Shares Spike Higher
www.nasdaq.com - September 7 at 4:00 PM
Cellect Biotechnology Announces $4.3 Million Raise in a Registered Direct OfferingCellect Biotechnology Announces $4.3 Million Raise in a Registered Direct Offering
finance.yahoo.com - September 7 at 4:00 PM
Cellect shares rise 5% after FDA grants its technology orphan drug statusCellect shares rise 5% after FDA grants its technology orphan drug status
finance.yahoo.com - September 6 at 8:57 PM
Cellect Granted FDA Orphan Nod, Shares SoarCellect Granted FDA Orphan Nod, Shares Soar
www.baystreet.ca - September 5 at 5:38 PM
Cellect Bios ApoGraft an Orphan Drug in U.S.; shares up 50% preamarketCellect Bio's ApoGraft an Orphan Drug in U.S.; shares up 50% preamarket
seekingalpha.com - September 5 at 5:38 PM
Cellect Biotechnology (APOP) Granted FDA Orphan Drug Designation for ApoGraftCellect Biotechnology (APOP) Granted FDA Orphan Drug Designation for ApoGraft
www.streetinsider.com - September 5 at 5:38 PM
FDA Grants Orphan Drug Status to Cellects ApoGraft™ for Acute GvHD and Chronic GvHDFDA Grants Orphan Drug Status to Cellect's ApoGraft™ for Acute GvHD and Chronic GvHD
finance.yahoo.com - September 5 at 5:38 PM
UPDATED: Cellect shares rise 53% after FDA grants its technology orphan drug statusUPDATED: Cellect shares rise 53% after FDA grants its technology orphan drug status
finance.yahoo.com - September 5 at 5:38 PM
Cellect Shares Will Be Traded From Next Week Exclusively on NASDAQCellect Shares Will Be Traded From Next Week Exclusively on NASDAQ
finance.yahoo.com - September 1 at 4:30 PM
Cellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial ResultsCellect Biotechnology Ltd Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 21 at 4:07 PM
Cellect Engages Locust Walk to Support Business Development Activities for Cellects ApoGraft™Cellect Engages Locust Walk to Support Business Development Activities for Cellect's ApoGraft™
finance.yahoo.com - August 7 at 4:50 PM
Cellect Biotechnology (APOP) Granted Russian Patent Covering Any Device & Method Using Flagship TechnologyCellect Biotechnology (APOP) Granted Russian Patent Covering Any Device & Method Using Flagship Technology
www.streetinsider.com - June 14 at 10:02 AM
Cellect Bio to delist shares on Tel Aviv exchange; ADRs will continue to trade on NasdaqCellect Bio to delist shares on Tel Aviv exchange; ADRs will continue to trade on Nasdaq
seekingalpha.com - June 5 at 6:19 PM
Cellect Biotechnology Gets European PatentCellect Biotechnology Gets European Patent
www.investopedia.com - April 3 at 8:53 PM
Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple IndicationsCellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications
us.rd.yahoo.com - April 3 at 3:52 PM
Cellect Succeeds in First Stem Cell TransplantCellect Succeeds in First Stem Cell Transplant
www.investopedia.com - March 27 at 3:41 PM
Cellect Biotech stock rises 71% after announcing successful stem cell transplant procedureCellect Biotech stock rises 71% after announcing successful stem cell transplant procedure
www.marketwatch.com - March 27 at 3:41 PM
Why Cellect Biotechnology Stock Is Skyrocketing TodayWhy Cellect Biotechnology Stock Is Skyrocketing Today
www.fool.com - March 27 at 3:41 PM
Cellect Biotechnology (APOP) Says It Treated First Blood Cancer Patient in Phase I/II Trial of ApoGraftCellect Biotechnology (APOP) Says It Treated First Blood Cancer Patient in Phase I/II Trial of ApoGraft
www.streetinsider.com - February 9 at 1:52 AM
First Cancer Patient Treated In Phase I/II Trial of ApoGraft™First Cancer Patient Treated In Phase I/II Trial of ApoGraft™
us.rd.yahoo.com - February 8 at 3:47 PM
Why Cellect Biotechnology Ltd Shares Skyrocketed Higher TodayWhy Cellect Biotechnology Ltd Shares Skyrocketed Higher Today
www.fool.com - February 8 at 3:47 PM
Cellect Biotechnology (APOP) Names Dr. Yaron Pereg as CDOCellect Biotechnology (APOP) Names Dr. Yaron Pereg as CDO
www.streetinsider.com - January 31 at 2:38 AM
Gainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRIGainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRI
www.finanznachrichten.de - January 13 at 1:38 AM
Cellect Biotechnology Ltd. (APOP) Is Surging On Patent NewsCellect Biotechnology Ltd. (APOP) Is Surging On Patent News
www.rttnews.com - January 12 at 8:38 PM
Cellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company’s Technology in Multiple Key IndicationsCellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company’s Technology in Multiple Key Indications
us.rd.yahoo.com - January 12 at 3:37 PM
Cellect appoints Eyal Leibovitz as CFOCellect appoints Eyal Leibovitz as CFO
seekingalpha.com - January 4 at 2:13 AM
Cellect Biotechnology Ltd. (APOP) Names Eyal Leibovitz as CFOCellect Biotechnology Ltd. (APOP) Names Eyal Leibovitz as CFO
www.streetinsider.com - January 4 at 2:13 AM
Cellect Announces Appointment of Eyal Leibovitz, Experienced Life Sciences Industry and Financial Executive, as Chief Financial OfficerCellect Announces Appointment of Eyal Leibovitz, Experienced Life Sciences Industry and Financial Executive, as Chief Financial Officer
us.rd.yahoo.com - January 3 at 4:08 PM
8:04 am Cellect Biotechnology appoints Eyal Leibovitz as CFO8:04 am Cellect Biotechnology appoints Eyal Leibovitz as CFO
us.rd.yahoo.com - January 3 at 4:08 PM
Form 6-K Cellect Biotechnology For: Sep 26Form 6-K Cellect Biotechnology For: Sep 26
www.streetinsider.com - September 26 at 8:16 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Cellect Biotechnology (NASDAQ APOP) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.